TB-500 and Thymosin Beta-4 Research: Related Names, Different Evidence
The short answer
Thymosin beta-4 is a naturally occurring 43-amino-acid peptide involved in actin binding and studied in cell migration, inflammation, angiogenesis and tissue-repair models. “TB-500” has been used for materials associated with a shorter thymosin beta-4 region, but the name does not by itself establish one universal sequence or equivalence to full-length thymosin beta-4.
That identity distinction controls how the evidence should be read. A result obtained with full-length thymosin beta-4 cannot automatically be assigned to a short fragment, an N-terminally modified fragment or a separately manufactured material sold under a related name.
Thymosin beta-4 biology
Thymosin beta-4 is abundant in many mammalian cells and can bind monomeric actin. Actin dynamics influence cell shape, movement and cytoskeletal organization. Researchers have therefore investigated thymosin beta-4 in cell migration, vascular responses, inflammation and repair biology.
These functions are context-dependent. A peptide associated with several cellular processes should not be described as producing one guaranteed organism-level outcome.
What has been studied preclinically?
Animal studies have investigated full-length thymosin beta-4 in dermal and corneal injury models. Published work in rodents reported changes in re-epithelialization, wound contraction, collagen deposition and other repair-associated measurements.
A seven-amino-acid actin-binding sequence, LKKTETQ, was also examined in an aged-animal wound model. Observing activity from a fragment in one model does not show that it reproduces every property of the parent peptide.
What does TB-500 identify?
A doping-control study described a veterinary TB-500 preparation containing N-terminally acetylated LKKTETQ, corresponding to residues 17–23 of thymosin beta-4. The researchers developed analytical methods to identify that fragment and its metabolites in equine samples.
This is useful identity evidence for the tested preparation. It does not prove that every commercial material called TB-500 has the same sequence, modification, purity or composition. The label name must be supported by material-specific analytical evidence.
Full-length and fragment evidence cannot be merged
Full-length thymosin beta-4 and a seven-residue fragment differ greatly in size and may differ in stability, distribution, target interactions and biological activity. A shared sequence region can provide a research rationale, but it is not proof of pharmacological equivalence.
Even where both materials affect a similar laboratory endpoint, the magnitude, concentration-response relationship and off-target profile may differ.
Human evidence boundaries
Clinical investigations have been reported for specific pharmaceutical preparations of thymosin beta-4, including topical wound and ocular research. Those studies concern the exact preparation, route, manufacturing controls and population tested. They do not establish clinical evidence for a TB-500 fragment or another research material.
The evidence base for systemic human use of materials marketed as TB-500 is not established by the cited full-length studies.
Analytical questions that matter
- What exact amino-acid sequence is present?
- Is the material full-length thymosin beta-4 or a fragment?
- Are terminal modifications specified and confirmed?
- Which analytical methods support identity, purity and quantity?
- Does the cited study test the same molecular material?
Sporting context
The World Anti-Doping Agency’s 2026 Prohibited List includes thymosin beta-4 and its derivatives, including TB-500. That sporting rule is separate from scientific evidence and Canadian health-product regulation, but it is relevant context for competitive athletes and support personnel.
Key points
- Thymosin beta-4 is a 43-amino-acid actin-binding peptide.
- TB-500 has been associated with a modified seven-amino-acid fragment in published analytical work.
- Parent-peptide evidence cannot automatically be transferred to a fragment.
- A commercial name does not establish sequence, purity or equivalence.
- Most repair-related evidence is preclinical or preparation-specific.
What this article does not establish
This article does not establish that an AURAPEP TB-500 material is full-length thymosin beta-4, equivalent to a cited preparation, safe or effective for injury recovery, or suitable for human use.
References
- Malinda KM, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999. https://pubmed.ncbi.nlm.nih.gov/10469335/
- Philp D, et al. Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in diabetic and aged mice. Wound Repair Regen. 2003. https://pubmed.ncbi.nlm.nih.gov/12581423/
- Goldstein AL, et al. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med. 2005. https://pubmed.ncbi.nlm.nih.gov/16099219/
- Ho ENM, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin beta4, in equine urine and plasma. Drug Test Anal. 2012. https://pubmed.ncbi.nlm.nih.gov/23084823/
- World Anti-Doping Agency. 2026 Prohibited List. https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf